Secukinumab Effective for Ankylosing Spondylitis in Phase 3 Trials
The interleukin-17A inhibitor secukinumab (Cosentyx, Novartis) was more effective than placebo at 16 weeks, with efficacy sustained to at least 52 weeks in patients with ankylosing spondylitis, according to interim phase 3 data from two trials, MEASURE 1 and MEASURE 2. The findings from both studies were published in the December 24 issue of the New England Journal of Medicine.
The researchers also reported that the effective maintenance dose for ankylosing spondylitis appears to be 150 mg/kg subcutaneously, given monthly.
“The results suggest that interleukin-17A plays a role in the pathogenesis of ankylosing spondylitis, and they validate inhibition of this cytokine as a potential therapeutic approach,” Dominique Baeten, MD, associate professor at the Department of Clinical Immunology and Rheumatology of the Academic Medical Centre/University of Amsterdam, the Netherlands, and colleagues write.
The current analyses are an expansion of data previously presented at the American College of Rheumatology 2014 Annual Meeting.
Secukinumab is approved in the United States for treatment of plaque psoriasis.
The MEASURE 1 study tested secukinumab as an intravenous loading dose of 10 mg/kg at baseline and weeks 2 and 4, followed by monthly subcutaneous doses of either 75 mg (n = 124) or 150 mg (n = 125) up to week 52 vs placebo (n = 122). This is a 2-year study followed by a 3-year extension study.